Novolink Health, previously known as Duxlink Health, has a decade of experience treating high-risk, high-cost patients from the comfort of their own homes. It will now function as a division within Florida-based Cardiovascular Associates of America.

Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. 

Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation. 

For most other specialties, however, starting salaries appear to be on the rise. 

CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology. 

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.

The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. 

The new medical device correction only includes a select number of devices. Abbott said they produce inaccurate readings, putting patient health at risk.